ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

FIPP Frontier Ip Group Plc

33.00
0.00 (0.00%)
04 Oct 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Frontier Ip Group Plc LSE:FIPP London Ordinary Share GB00B63PS212 ORD 10P
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.00% 33.00 36,914 08:00:00
Bid Price Offer Price High Price Low Price Open Price
32.00 34.00 33.00 33.00 33.00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Real Estate Agents & Mgrs 372k -3.24M -0.0578 -5.71 18.54M
Last Trade Time Trade Type Trade Size Trade Price Currency
16:25:37 O 23,892 32.15 GBX

Frontier Ip (FIPP) Latest News

Frontier Ip (FIPP) Discussions and Chat

Frontier Ip Forums and Chat

Date Time Title Posts
30/9/202413:17Frontier IP838
30/7/201123:11Why have they bothered1

Add a New Thread

Frontier Ip (FIPP) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type

Frontier Ip (FIPP) Top Chat Posts

Top Posts
Posted at 06/10/2024 09:20 by Frontier Ip Daily Update
Frontier Ip Group Plc is listed in the Real Estate Agents & Mgrs sector of the London Stock Exchange with ticker FIPP. The last closing price for Frontier Ip was 33p.
Frontier Ip currently has 56,166,946 shares in issue. The market capitalisation of Frontier Ip is £18,535,092.
Frontier Ip has a price to earnings ratio (PE ratio) of -5.71.
This morning FIPP shares opened at 33p
Posted at 25/9/2024 07:51 by aqc888
Lots of great news… A highly regarded investor increasing their stake… A rare example of an AIM CEO taking his own medicine in bulk with a huge holding… Importantly people within the industries of portfolio companies singing the praises of new technology… Proven track record with exscentia… yet the share price is at a near 8yr low. Bizarre
Posted at 23/9/2024 21:45 by aqc888
Given this constant positive news flow, would one expect the NAV to be fairly positive on 31st October. The frontier share price always seems to be taken by surprise when results are out…
Posted at 05/9/2024 12:09 by rivaldo
Thanks acuere, so many gems in the porfolio. Hopefully the seller(s) are out and the share price will recover back to 50p-60p tout suite.
Posted at 13/8/2024 10:23 by jimmywilson612
Lets see what tomorrow brings - I don't think it'll materially affect FIPP share price short term....

but if its a product release date/improved etc then why wait until tomorrow and not just make the announcement, unless it needs to be tied into an agreement elsewhere with another company....
Posted at 11/8/2024 20:27 by aqc888
The entire FTSE AIM market is also at a 5year low. We also saw Milton selling a large part of their shares in Frontier last year. There’s a void of information on how the portfolio is doing. I’d point out that when the annual results come they usually point to success and the share price rises subsequently. When you compare Frontier to rivals their portfolio is diversified and strong in my opinion.
Posted at 18/3/2024 11:54 by rivaldo
FIPP are featured on i.i.i as an AIM growth share to consider:



"Frontier IP (FIPP)

Price: 42p

Technology investment company Frontier IP Group FIPP is different to the other companies because if it makes a profit it tends to be because of gains in its portfolio company valuations or those realised via disposals. Management’s relationships with a number of universities in the UK and Portugal provide it with opportunities. There are parts of the portfolio that are starting to mature and provide exits.

The model is that Frontier IP earns stakes in technology spin-outs in return for providing advice and services and not from investing cash directly. In the six months to December 2023, the net asset value (NAV) increased from 81.8p/share to 84.2p/share thanks to higher portfolio valuations and a sale of Exscientia shares.

Nasdaq listed investee company Exscientia is an example of the potential for gains, although not all early-stage portfolio investments will do well. Exscientia is a spin-out from the University of Dundee and uses artificial intelligence to help drug discovery. Frontier IP has raised £14 million from share sales, whereas the cost of the investment was less than £2,000.

Another investee company Alusid, a spin-out from the University of Central Lancashire, produces sustainable tiles and could be on course for a flotation. Other investee companies are making progress with Heriot Watt University spin-out Nandi Proteins singing a commercial licence with a global food ingredients company.

There was cash of £2.7 million at the end of 2023, while a further £1.7 million was subsequently raised from selling the remaining Exscientia shares.

There has been a sharp recovery in the share price this year, but it is still 45% lower than at the end of 2022. The 50% discount to NAV partially reflects the fact that the portfolio is predominantly unquoted. Even so, this discount is too high and should narrow, while positive news on Alucid could provide further upside."
Posted at 09/2/2024 10:19 by acuere
I share your frustration at the lack of news on ustake. The trouble is I’m not fully au fait with how long discussions, testing and product designs take. When we hear they are in talks with majors and then hear nothing for ages we just don’t know if talks are still ongoing or if they walked away. For now I’m happy to accept they are still on track with discussions etc.
I’d also add that if I was invested in Pulsiv PLC and they were valued at say £200m then I might be more concerned. But at a value of £50m, which as Fipp share price at 40%+ discount to Nav effectively makes their value £30m I am not concerned. And remember that £50m value is from November 2022. They have made huge progress and strengthened the board since then.
The other thing I’d ask is have you spoken to Pulsiv about your concerns? At least 3 posters on here have done. It might provide you with some reassurance.
Posted at 29/1/2024 10:04 by rivaldo
Cheers acuere, excellent news.

Here's ST's full tip for FIPP in the IC:

"Back future tech winners via Frontier IP

Smart technology funds are investing in tile company Alusid ahead of an IPO – and so can you through this below-the-radar investment company

January 22, 2024
by Simon Thompson

Portfolio attracts high-profile technology investor
50 per cent share price discount to NAV

Edinburgh-based Frontier IP (FIPP:40p), a technology investment company that provides commercialisation services to university spin-outs in return for ‘free equity’ stakes, has announced a successful capital raise for portfolio company Alusid. Alusid creates premium-quality tiles and architectural surfaces
by recycling industrial waste ceramics, glass and other materials, much of which would end in landfill.

As part of a larger £1.13mn funding round, Octopus AIM VCT funds are investing £0.5mn in Alusid, which values the company at £9.5mn. Frontier IP holds a 35.4 per cent equity stake in Alusid worth £3.3mn. The cash proceeds will be used to support Alusid's expansion into new product ranges and territories. For instance, the
company is developing hard-wearing floor tiles, which are expected to launch commercially this year, and is in discussions with potential distributors in Scandinavia and Northern Europe. It is also exploring options for an IPO later this year.

There is clear momentum in Alusid’s business. In the past year, the company has launched environmentally friendly products with Topps Tiles, the UK's largest tile retailer, and is in collaboration with Imerys, a world leader in speciality minerals, to develop floor tiles. Other customers include H&M, Pret a Manger, BBC and Starbucks.

Prospects for further gains on Frontier’s portfolio are being woefully undervalued. To put this into perspective, Frontier holds a liquid £2.3mn stake in Nasdaq-listed Exscientia (US: EXAI)Exscientia (US: EXAI), a clinical-stage pharmaceutical technology company, pro-forma cash of £2.5mn (after factoring in operating expenses in the past six months), a £33mn equity portfolio, £5.9mn of debt investments and £1mn of trade receivables.

Ignoring the possibility of valuation uplifts in the forthcoming interim results, the £22.5mn market capitalisation company is rated on a 50 per cent discount to book value.

That’s an extreme discount considering the progress being made by multiple investee
companies including its largest holding, Plymouth University spin-out Pulsiv Solar, a green technology company that has developed on-chip technology to improve the energy efficiency of power supplies, battery chargers, LED lighting and photovoltaic solar cells.

Frontier IP’s 18 per cent stake in Pulsiv had a read-through valuation of £9.3mn following Pulsiv's last fundraising. So, although Frontier IP’s share price is slightly shy of my last buy call (‘Bag a technology bargain buy’, 31 October 2023), there is a clear disconnect between the value embedded in an exciting investment portfolio and the price attributed to its investments by the market. Buy."
Posted at 02/11/2023 11:10 by rivaldo
For the record, here's the IC's new FIPP tip:

"Bag a technology bargain buy

A 50 per cent discount to NAV is harsh given the operational progress being made by the group’s investee companies

NAV falls 6.5 per cent to £45.5mn (81.8p)
Cash and listed stake in Exscentia currently worth £6.2mn (11.1p)
Progress on multiple investee companies

Shares in Edinburgh-based FrontierIP (FIPP:41.5p), a technology investment company that provides commercialisation services to university spin-outs in return for ‘free equity’stakes, dipped 10 per cent post annual results.The fall was caused by an unexpected 6.5 percent (£3.1mn) reversal in net asset value (NAV)after the group booked a £2.2mn unrealised loss on its 17 per cent stake in The Vaccine Group(TVG).

TVG is creating a range of vaccines based on a novel herpes virus-based platform to prevent the spread of economically damaging diseases in livestock. The company now has eight vaccine candidates approaching proof of principle. Its most advanced projects are for pigs. During the year, TVG successfully developed a vaccine candidate for streptococcus suis, a bacterial disease carried by pigs that causes productivity losses as well as meningitis and other symptoms in humans. The project was funded by the UK and Chinese governments.

In addition to streptococcus suis, TVG has developed a transmissible candidate vaccine against a virus called Lassa fever for use in ratsthat spread the disease. Funded by a US government agency, a small-scale trial showed the candidate could be transmitted between rats,significantly improving their immunity to Lassa fever and reducing its spread between them. The company is in discussions with potential partners.Progress on monetising its technology will be needed to drive TVG’s valuation higher, but that’s not out of the question.

It’s something that Plymouth spin-out, green technology company Pulsiv Solar, the group’s largest holding, is already doing. Its on-chip technology not only improves the energy efficiency of power supplies, battery chargers, LED lighting and photovoltaic solar cells, but is proving popular with leading electronic component suppliers around the world looking to exploit the commercial opportunity. A £1.5mn fundraising placed a £50mn pre-money valuation on Pulsiv,which means that Frontier’s 18.2 per cent equity stake has a read-through valuation of £9.4mn,accounting for 28 per cent of its £33mn equity portfolio at the 30 June 2023 financial year-end.

The operational progress of harvest robotics developer Fieldwork Robotics, a spin-out from the University of Plymouth, is also attracting investor interest. Post Frontier’s financial year-end, the company secured a £1.5mn investmentfrom Elbow Beach Capital, a decarbonisation,sustainability and social impact investor, and attracted £1.5mn of investment from 575 investors in a Seedrs funding round. The £7.2mn pre-money valuation placed a £1.6mn value on Frontier’s equity stake. Having developed the world's first raspberry-harvesting robots to improve farm efficiency, reduce food wastage and help solve the problem of worker shortages,the funds raised are being used to grow Fieldworks’ team, outsource robot manufactureand attract more farmers to its harvest-as-a-service offering.

It’s a similar positive story at Cambridge University spin-out CamGraPhIC. The company’s graphene-based photonics run at higher speeds and lower temperatures than equivalent technologies – and therefore use less energy. Datacentres, which consume around 1 per cent of global energy output, are one potential marketfor its optical transceivers. Sir Michael Rake,former chair of BT Group(BT.A), invested in CamGraPhIC’s latest funding round, which raised £1.26mn to complete the fabrication and testing of demonstration devices with multinational companies. The technology is starting to gain traction with governmental organisations, too. In the financial year, Frontier booked a £1.4mn gain on its 20.8 per cent stake in CamGraPhIC, in line with the fundraising valuation, and a £0.7mn gain on its £2.6mn loan note holding.

Deep discount to sum-of-the-parts valuations

Post period end, Frontier IP subscribed for a further £1.3mn of CamGraPhIC loan notes (of which £0.8mn was classified as Advances in the2023 accounts) to accelerate its development.The investment reduces group pro-forma cash to £4.1mn. In addition, Frontier intends to dispose of more shares in Nasdaq-listed Exscientia (US:Exscientia(EXAI), a clinical-stage pharma technology company pioneering the use of artificial intelligence (AI) to design new drugs. Frontier currently holds 0.49mn Exscientia shares worth $2.5mn (£2.1mn) at the current market price.

Effectively, the liquid stake in Exscientia and pro-forma cash are worth £6.2mn (11.1p) or a quarter of the group’s market capitalisation of £23mn (41.5p). It means that Frontier’s £33mn(59p) equity portfolio, £5.9mn (10.5p) of debt investments and £1mn (1.8p) of trade receivables are in the share price for 58 per cent less than their combined carrying valuations.That̵7;s extremely harsh given the progress being made by both CamGraPhIC and Pulsiv Solar. In fact, I would be surprised if their combined valuation doesn’t exceed Frontier’s current market capitalisation within the next 18-24months.So, having made a case to buy Frontier’s shares,at 38p, ahead of the results (‘A tech buy on a 57 per cent discount’, 13 September 2023), I see scope for positive newsflow from portfolio companies to narrow the 50 per cent share price discount to NAV over the coming months. Buy"
Posted at 23/5/2023 13:47 by acuere
A lot of the AI pharmas jumped sharply yesterday. Exai presenting at SLAS this week and sentences like this from us,
“ We believe that within this decade the design of all new drug candidates will be augmented with AI.” would surely stimulate investors appetite for these stocks. Hopefully Exai can hold these share price gains. Not that it seems to make any difference to Fipp share price Exai are up about 50% this year and yet Fipp over 20% down.

I think we need a juicy Pulsiv announcement or confirmation of Allusid IPO to get things moving in the right direction again.
Frontier Ip share price data is direct from the London Stock Exchange

Your Recent History

Delayed Upgrade Clock